Giordano Christopher Thomas
Known title: CEOCIK: 0001871714
Giordano Christopher Thomas's purchase track record
Giordano Christopher Thomas has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/11/2026 | TENX | $20K | pending | pending | — |
| 11/18/2025 | TENX | $20K | +62.4% | +49.3% | +11.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TENX | ▲ Buy | Open Market | 4,850 | $9K | 9/15/2026 | View on chart |
| TENX | ▲ Buy | Open Market | 6,000 | $11K | 9/11/2026 | View on chart |
| TENX | ▲ Buy | Option Exercise | 219 | $777 | 7/13/2026 | View on chart |
| TENX | ▲ Buy | Option Exercise | 8,500 | $50K | 7/13/2026 | View on chart |
| TENX | ▲ Buy | Open Market | 538 | $4K | 11/20/2025 | View on chart |
| TENX | ▲ Buy | Open Market | 455 | $3K | 11/19/2025 | View on chart |
| TENX | ▲ Buy | Open Market | 1,612 | $13K | 11/18/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting
Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting. Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.